New FDA designation opens the door for stem cell trials

Dr. Temple contributed to a recent article on a stem cell clinical trial that has recently received the Food and Drug Administration’s new Regenerative Medicine Advanced Therapy (RMAT) designation.

Read more about how this new designation will help to promote the advancement of legitimate stem cell therapies:–Antibody-Engineering/

Dr. Messer hosts webinar for “The Scientist”

Dr. Anne Messer was one of two experts chosen to present a webinar for The Scientist (March 8, 2018.) Antibodies are the fastest growing class of synthetic therapeutics, and Dr. Messer’s presentation covered their development and use as therapeutics and markers for neurodegenerative diseases. She described cutting-edge design and optimization approaches, as well as offering insight on future directions in antibody engineering. Human stem cell lines and assays at NSCI allow screening and testing for which of these engineered antibodies and their variants should be carried forward as clinical drug candidates. The session had 581 registrants and 148 live viewers who also asked questions at the end of the presentations.–Antibody-Engineering/

Support NSCI on November 28th, #GivingTuesday


Celebrate your kindness on #GivingTuesday.

On #GivingTuesday, a national day of donation, consider a gift to the Neural Stem Cell Institute. Your gift gets us closer to therapies for incurable diseases of the central nervous system including Macular Degeneration, Alzheimer’s, Parkinson’s, Spinal Cord Injury and Autism. Your support inspires our ongoing research and brings us closer to cures.

Your gracious contribution can be made by clicking here. Or, by mailing a check made out to Regenerative Research Foundation to: 1 Discovery Drive, Rensselaer, NY 12144.

Or, as you begin your holiday shopping simply include us through Amazon Smile. When you shop at Amazon the AmazonSmile Foundation will donate 0.5% of the purchase price from your eligible purchases.

  1. Go to ,
  2. log in to your amazon account
  3. Choose “Regenerative Research Foundation” in Rensselaer, it should look like this…
  4. Now, when ever you shop at Amazon you’ll see that you are supporting us…

However you choose to give, we celebrate your support. Your gift gets us closer to helping so many.  Thank you!

NSCI Researchers Presenting at NYAS

This week Dr. Boles and Dr. Kiehl will be attending a workshop on “Data Science, Learning, and Applications to Biomedical & Health Sciences” at the New York Academy of Sciences (NYAS) in New York City. This workshop is jointly sponsored by the National Science Foundation, Rutgers Institute for Data Science, learning, and Applications (I-DSLA), Columbia University Data Science Institute and the NYAS.
Dr. Boles will present their work in a talk entitled “Big Data Access and Infrastructure: Case Studies in Data Repository Utility.” In this talk he will address the needs of biological researchers to access and analyze large,complex, data sets.
NSCI will also be represented with two other posters dealing with big data as it relates to particular efforts at the institute and to small organizations.
  • Regarding engaging big data with limited resources – “Big Data and Small Labs: Nose-to-tail informatics on the front lines of the data deluge”
  • In collaboration with Dr. Charles Bergeron from Albany College of Pharmacy and Health Sciences – “A pipeline for a growing data resource: Electrophysiological behavior of in-vitro cell cultures”
Find out more about the workshop at the NYAS website. From the workshop organizers:
This workshop aims to develop a research agenda for this area and enable connections and collaborations among scientists from academia, industry, and government, clinicians and investigators engaged in technology development, deployment, and use.
The workshop will provide a forum for these investigators to assess the state-of-the-art, identify related challenges and propose solutions to address enhancing the utility of “Big Data”. The overarching goal of these endeavors will be to incorporate the capabilities of ‘Big Data” technology toward understanding normal biological and disease processes at the population, individual patient, and cellular levels.”

#GivingTuesday 2015


What is #GivingTuesday?

“We have a day for giving thanks…now, we have #GivingTuesday, a global day dedicated to giving back. On Tuesday, December 1, 2015, charities, families, businesses, community centers, and students around the world will come together for one common purpose: to celebrate generosity and to give.”

Why give? Why now? Why us?

The holidays are close and so many things need my attention: shopping for holiday meals, a hair cut for my son, new clothes my daughter. I will want buy gifts for my dear family and friends. Especially now, the daily demands on my time and budget are innumerable. I ask myself, why give, why now?  

Right now we are healthy. My aging parents don’t struggle with disease. My children are thriving. We are so very lucky.

What will my small gift do? And what does giving to research really accomplish?

My friend has macular degeneration. I watched my grandmother lose her clarity to Alzheimer’s to the point of not recognizing her daughter, my mother. I have a colleague whose daughter lost her eye to retinoblastoma, a rare cancer of the eye. My cousin’s son has autism. Will my small gift change their lives?  I don’t want to risk the possibility that it might. And without my gift, it surely will not.

Every gift helps quicken the pace of research.

NSCI is the first private stem cell institute in the US.  We have a history of turning small gifts into progress….

-NSCI is currently using stem cells to model Parkinson’s Disease and Alzheimer’s Disease to understand why the cells in the brain degenerate and identify novel drugs to prevent this.

-NSCI uses stem cells to model the early stages of brain development to understand how it is affected in Autism.

-NSCI has discovered a stem cell population in the human eye with the ability to generate cells that can be transplanted into Macular Degeneration patients.  NSCI has translated this discovery into a therapeutic product that is on track to begin an FDA approved clinical trial in 2017.

-NSCI has developed a novel way to encourage stem cells in an injured spinal cord to activate and promote repair.

Your generosity and partnership can be powerful tools enabling scientific discovery. Help us build the foundation that future therapy and treatments will be built on.

Click here to give today.